Leukemia screening involves detection of abnormalities in white blood cells to diagnose various types of leukemia such as acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia and chronic lymphocytic leukemia. Advanced diagnostics techniques including flow cytometry, fluorescence in situ hybridization and polymerase chain reaction help analyzing cells, genes and chromosomes at molecular level for precise diagnosis and disease monitoring. This improves treatment outcomes and aids in timely intervention. The global Leukemia Screening Market is estimated to be valued at US$ 7.28 Bn in 2023 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The availability of advanced diagnostics has accelerated the growth of the leukemia screening market. Advanced diagnostics techniques such as Next Generation Sequencing help in detecting gene mutations with high sensitivity. This allows Healthcare providers to determine the appropriate treatment strategy for leukemia patients. Next Generation Sequencing also monitors treatment response and detects residual disease post-treatment, aiding timely intervention. As a result, key players are focused on developing and commercializing advanced diagnostics solutions for precise diagnosis and effective management of leukemia. For instance, In 2020, ArcherDX, Inc. launched theResponse Dx Pan-Cancer assay based on Next Generation Sequencing for monitoring treatment response and residual disease detection in cancer patients including leukemia patients.
Segment Analysis
Leukemia is classified into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). Acute lymphocytic leukemia accounts for the largest market share as it is the most common type of leukemia affecting children. ALL makes up around 75-80% of all childhood leukemias. Early diagnosis can vastly improve treatment outcomes for ALL.
Key Takeaways
The global leukemia screening market is expected to witness high growth at a CAGR of 7% during the forecast period of 2023-2030 to reach a market size of US$ 7.28 billion by 2030.
Regional analysis
North America currently dominates the leukemia screening market due to high awareness levels regarding leukemia, presence of leading market players, and advanced healthcare infrastructure. However, Asia Pacific is expected to register the fastest growth during the forecast period due to rising healthcare expenditure, increasing per capita income, growing geriatric population in China and India.
Key players
Key players operating in the leukemia screening market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., QIAGEN N.V., Beckman Coulter, Inc., Adaptive Biotechnologies Corporation, Invivoscribe, Inc., and ArcherDX, Inc. F. Hoffmann-La Roche Ltd offers leukemia screening tests such as FISH probes and RT-PCR kits.
No comments:
Post a Comment